PAPER Müller T, TANIMOS Study Investigators

Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Ther Adv Neurol Disord. 2014 Mar;7(2):77-82. PubMed: 24587824

PAPER Evans AH, Kettlewell J, McGregor S, Kotschet K, Griffiths RI, Horne M

A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

PLoS One. 2014;9(2):e89319. Epub 2014 Feb 24 PubMed: 24586685

PAPER Yu WJ, Li NN, Tan EK, Cheng L, Zhang JH, Mao XY, Chang XL, Zhao DM, Liao Q, Peng R

No association of four candidate genetic variants in MnSOD and SYNIII with Parkinson's disease in two Chinese populations.

PLoS One. 2014;9(2):e88050. Epub 2014 Feb 26 PubMed: 24586301

PAPER Hartfield EM, Yamasaki-Mann M, Ribeiro Fernandes HJ, Vowles J, James WS, Cowley SA, Wade-Martins R

Physiological characterisation of human iPS-derived dopaminergic neurons.

PLoS One. 2014;9(2):e87388. Epub 2014 Feb 21 PubMed: 24586273

PAPER Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell'aquila C, De Mari M, Ferranini E, Bonifati V, Pacelli C, Cocco T

Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease.

Biochim Biophys Acta. 2014 Jul;1842(7):902-15. Epub 2014 Feb 25 PubMed: 24582596

PAPER Tambosco L, Percebois-Macadré L, Rapin A, Nicomette-Bardel J, Boyer FC

Effort training in Parkinson's disease: a systematic review.

Ann Phys Rehabil Med. 2014 Mar;57(2):79-104. Epub 2014 Feb 11 PubMed: 24582335

PAPER Marras C, Hincapié CA, Kristman VL, Cancelliere C, Soklaridis S, Li A, Borg J, af Geijerstam JL, Cassidy JD

Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis.

Arch Phys Med Rehabil. 2014 Mar;95(3 Suppl):S238-44. PubMed: 24581909

PAPER Anheim M

[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].

Rev Neurol (Paris). 2014 Feb;170(2):89-90. PubMed: 24581302

PAPER Golbe LI

The tau of PSP: A long road to treatment.

Mov Disord. 2014 Mar 1; PubMed: 24585428

PAPER Liu F, Xue Z, Li N, Huang H, Ying Y, Li J, Wang L, Li W

Effects of lead exposure on the expression of amyloid β and phosphorylated tau proteins in the C57BL/6 mouse hippocampus at different life stages.

J Trace Elem Med Biol. 2014 Apr;28(2):227-32. Epub 2014 Jan 29 PubMed: 24582137

Guinevere Lourenco

Neuroscience Research Australia
Australia

BACE Inhibitor Heads for Phase 2/3 Trials

RESEARCH NEWS 2014-03-04 Research News AstraZeneca’s BACE inhibitor AZD3293  has passed Phase 1 safety tests and will enter a large international Phase 2/3 trial later this year, said Samantha Budd from the company’s Cambridge, Massachusetts, site. The news comes after Merck’s De

Joana Gil-Mohapel on Neurogenesis in the striatum of the adult human brain.

COMMENT It was well known that the human brain retains a certain degree of plasticity throughout postnatal and adult life. Adult hippocampal neurogenesis has been known to occur in the human brain since the pioneer study by Eriksson and colleagues (Eriksson et al

PAPER Kempermann G

Off the beaten track: new neurons in the adult human striatum.

Cell. 2014 Feb 27;156(5):870-1. PubMed: 24581487

Massimo Grilli

University of Genova
Genoa, Italy